+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
ID07581002

Randomized Study of Pivekimab Sunirine With Venetoclax and Azacitidine Versus Standard Treatment in Adults With Newly Diagnosed AML Not Eligible for Intensive Chemotherapy

Led by AbbVie · Updated on 2026-10-22

660

Participants Needed

38

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effects of Pivekimab Sunirine PVEK combined with Venetoclax VEN and Azacitidine AZA in adults newly diagnosed with acute myeloid leukemia AML who cannot receive intensive chemotherapy. AML is a blood and bone marrow cancer affecting white blood cells and normal blood cell production. This Phase 23 study involves a randomized design with about 660 participants worldwide to assess adverse events and changes in disease activity. Participants will receive either PVEK plus VEN and AZA or standard care treatments. In Phase 2, treatments are open-label and randomized, while Phase 3 uses a double-blind randomized design where some receive a placebo matching PVEK. PVEK is administered intravenously, AZA either by injection under the skin or intravenously depending on location, and VEN is taken orally as a tablet. The full study lasts about 71 months, with participants receiving regular treatment infusions, injections, and oral medication. During the study, participants will attend frequent visits at hospitals or clinics for medical assessments, blood tests, and monitoring for side effects. Researchers will measure outcomes like complete remission rates, overall survival, quality of life changes, transfusion independence, and adverse events over the study period. This follow-up helps evaluate the safety and impact of the treatments on AML disease activity and participant well-being.

CONDITIONS

Brief Title

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

Research Team

A

ABBVIE CALL CENTER

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here